In DepthCANCER

Is genome-guided cancer treatment hyped?

See allHide authors and affiliations

Science  27 Apr 2018:
Vol. 360, Issue 6387, pp. 365
DOI: 10.1126/science.360.6387.365

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

For people with advanced cancer who are running out of options, many cancer centers now offer this hope: Have your tumor's genome sequenced, and doctors will match you with a drug that targets its weak spot. But this booming area of cancer treatment has critics, who say its promise has been oversold. Last week, two prominent voices in the field faced off in a sometimes-tense debate on what's often called precision oncology at the annual meeting of the American Association for Cancer Research in Chicago, Illinois. Their dispute threw a splash of cold water on a meeting packed with sessions on genome-based cancer treatments.